ATE311373T1 - Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen - Google Patents
Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffenInfo
- Publication number
- ATE311373T1 ATE311373T1 AT00913480T AT00913480T ATE311373T1 AT E311373 T1 ATE311373 T1 AT E311373T1 AT 00913480 T AT00913480 T AT 00913480T AT 00913480 T AT00913480 T AT 00913480T AT E311373 T1 ATE311373 T1 AT E311373T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- active ingredients
- oxadiazole compounds
- delivering active
- oxadiazole
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000004866 oxadiazoles Chemical class 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processing Of Solid Wastes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11963899P | 1999-02-11 | 1999-02-11 | |
| PCT/US2000/003899 WO2000047188A1 (en) | 1999-02-11 | 2000-02-11 | Oxadiazole compounds and compositions for delivering active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311373T1 true ATE311373T1 (de) | 2005-12-15 |
Family
ID=22385472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00913480T ATE311373T1 (de) | 1999-02-11 | 2000-02-11 | Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1156787B1 (de) |
| JP (1) | JP4854855B2 (de) |
| AT (1) | ATE311373T1 (de) |
| AU (1) | AU3492100A (de) |
| CA (1) | CA2360220C (de) |
| DE (1) | DE60024414T2 (de) |
| ES (1) | ES2251976T3 (de) |
| WO (1) | WO2000047188A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6461643B2 (en) | 1993-04-22 | 2002-10-08 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US6358504B1 (en) | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU2003208945B2 (en) | 2002-02-20 | 2008-05-01 | Emisphere Technologies, Inc | Method for administering GLP-1 molecules |
| CN100368461C (zh) | 2003-03-05 | 2008-02-13 | 东丽株式会社 | 芳香族高分子、膜、电解质膜和隔板 |
| EP1658273B1 (de) | 2003-08-20 | 2007-01-03 | Eli Lilly And Company | Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids |
| ES2286679T3 (es) * | 2003-08-20 | 2007-12-01 | Eli Lilly And Company | Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4). |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| NZ550894A (en) | 2004-05-06 | 2011-02-25 | Emisphere Tech Inc | Solid dosage form of wetted heparin |
| AU2005249410A1 (en) | 2004-05-14 | 2005-12-15 | Emisphere Technologies, Inc. | Aryl ketone compounds and compositions for delivering active agents |
| ES2393324T3 (es) | 2004-05-14 | 2012-12-20 | Emisphere Technologies, Inc. | Compuestos y composiciones para administrar principios activos |
| BRPI0510820A (pt) | 2004-05-19 | 2007-11-27 | Emisphere Tech Inc | composição farmacêutica, forma unitária de dosagem e seus usos |
| BRPI0510906A (pt) | 2004-05-19 | 2007-11-06 | Emisphere Tech Inc | composição farmacêutica tópica, composição para administração tópica e seu uso |
| AU2005271526B2 (en) | 2004-08-03 | 2011-12-08 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| MX2007008082A (es) | 2004-12-29 | 2007-09-05 | Emisphere Tech Inc | Formulaciones farmaceuticas de sales de galio. |
| US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| WO2007011958A2 (en) | 2005-07-15 | 2007-01-25 | Emisphere Technologies, Inc. | Intraoral dosage forms of glucagon |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| WO2007133944A2 (en) | 2006-05-09 | 2007-11-22 | Emisphere Technologies, Inc. | Topical administration of acyclovir |
| WO2008003050A2 (en) | 2006-06-28 | 2008-01-03 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
| ES2579229T3 (es) | 2007-03-13 | 2016-08-08 | Jds Therapeutics, Llc | Procedimientos y composiciones para la liberación sostenida de cromo |
| WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| US20110039930A1 (en) | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| AU2012223282B2 (en) | 2011-03-01 | 2017-02-02 | Nutrition 21, Llc | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
| CN103265538B (zh) * | 2013-02-19 | 2015-08-05 | 中国人民解放军南京军区南京总医院 | 一种氮唑类抗真菌化合物及其制备方法和应用 |
| TN2016000127A1 (en) | 2013-12-20 | 2017-10-06 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors. |
| AU2017217466A1 (en) | 2016-02-11 | 2018-08-23 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2765304A (en) * | 1952-05-21 | 1956-10-02 | Ciba Ltd | New ox-diazole compounds and process for their manufacture |
| US3964896A (en) * | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
| JPS5182393A (ja) * | 1974-12-30 | 1976-07-19 | Furukawa Electric Co Ltd | Shinkinaamidoimidojushinoseizoho |
| DE2651386A1 (de) * | 1976-11-11 | 1978-05-18 | Hoechst Ag | Cephemderivate und verfahren zu ihrer herstellung |
| EP0109362A1 (de) * | 1982-11-16 | 1984-05-23 | Ciba-Geigy Ag | Heterocyclylverbindungen, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, welche diese Verbindungen enthalten, und Verwendung von letzteren |
| US5541155A (en) * | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
| US5714167A (en) * | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| FR2672050A1 (fr) * | 1991-01-30 | 1992-07-31 | Atochem | Diaryl-2,5 oxadiazoles-1,3,4 hydroxyester, hydroxyacide et acetoxyacide, leur procede de synthese. |
| DE4302051A1 (de) * | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO1996011210A1 (en) * | 1994-10-07 | 1996-04-18 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic hexapeptides having antibiotic activity |
| US5668159A (en) * | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
-
2000
- 2000-02-11 WO PCT/US2000/003899 patent/WO2000047188A1/en not_active Ceased
- 2000-02-11 ES ES00913480T patent/ES2251976T3/es not_active Expired - Lifetime
- 2000-02-11 EP EP00913480A patent/EP1156787B1/de not_active Expired - Lifetime
- 2000-02-11 CA CA002360220A patent/CA2360220C/en not_active Expired - Fee Related
- 2000-02-11 JP JP2000598141A patent/JP4854855B2/ja not_active Expired - Fee Related
- 2000-02-11 DE DE60024414T patent/DE60024414T2/de not_active Expired - Lifetime
- 2000-02-11 AU AU34921/00A patent/AU3492100A/en not_active Abandoned
- 2000-02-11 AT AT00913480T patent/ATE311373T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3492100A (en) | 2000-08-29 |
| DE60024414D1 (de) | 2006-01-05 |
| CA2360220A1 (en) | 2000-08-17 |
| ES2251976T3 (es) | 2006-05-16 |
| DE60024414T2 (de) | 2006-06-14 |
| JP4854855B2 (ja) | 2012-01-18 |
| WO2000047188A1 (en) | 2000-08-17 |
| JP2002536400A (ja) | 2002-10-29 |
| CA2360220C (en) | 2009-09-08 |
| EP1156787B1 (de) | 2005-11-30 |
| EP1156787A4 (de) | 2002-04-24 |
| EP1156787A1 (de) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE387430T1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| AU7315301A (en) | Compounds and compositions for delivering active agents | |
| MXPA01008611A (es) | Compuestos y composiciones para suministrar agentes activos. | |
| IL140930A0 (en) | Compounds and compositions for delivering active agents | |
| ATE383169T1 (de) | Komponente und zusammensetzungen zur verabreichung von wirkstoffen | |
| EP1226109A4 (de) | Phenylamin-carbonsäure-verbindungen und zubereitungen zur verabreichung von wirkstoffen | |
| DE60024414D1 (de) | Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen | |
| MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
| IL140710A0 (en) | Pulmonary delivery of active agents | |
| MXPA04004567A (es) | Compuestos y composiciones de fenoxi amina para adminstrar agentes activos. | |
| FI971776A0 (fi) | Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi | |
| AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| WO2002015959A3 (en) | Compounds and compositions for delivering active agents | |
| DE60334773D1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| DE69819145D1 (de) | Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung | |
| EP1676832A3 (de) | Verbindungen und Zusammentsetzungen zur Freisetzung von Aktivstoffen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |